DUBLIN--(BUSINESS WIRE)--The "Porphyria - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Porphyria - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Porphyria development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Porphyria Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products In Clinical Stage
6. Products In Pre-Clinical And Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Companies Mentioned
- Alnylam Pharmaceuticals
- Clinuvel Pharmaceuticals Limited
- Digna Biotech
- UniQure N.V.
- Palatin Technologies
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bfwqth/porphyria?w=4.
